The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation
- 1 October 2014
- journal article
- research article
- Published by Archives of Pathology and Laboratory Medicine in Archives Of Pathology & Laboratory Medicine
- Vol. 138 (10), 1387-1405
- https://doi.org/10.5858/arpa.2014-0219-sa
Abstract
Context.—Prostate cancer remains a significant public health problem. Recent publications of randomized trials and the US Preventive Services Task Force recommendations have drawn attention to overtreatment of localized, low-risk prostate cancer. Active surveillance, in which patients undergo regular visits with serum prostate-specific antigen tests and repeat prostate biopsies, rather than aggressive treatment with curative intent, may address overtreatment of low-risk prostate cancer. It is apparent that a greater awareness of the critical role of pathologists in determining eligibility for active surveillance is needed. Objectives.—To review the state of current knowledge about the role of active surveillance in the management of prostate cancer and to provide a multidisciplinary report focusing on pathologic parameters important to the successful identification of patients likely to succeed with active surveillance, to determine the role of molecular tests in increasing the safety of active surveillance, and to provide future directions. Design.—Systematic review of literature on active surveillance for low-risk prostate cancer, pathologic parameters important for appropriate stratification, and issues regarding interobserver reproducibility. Expert panels were created to delineate the fundamental questions confronting the clinical and pathologic aspects of management of men on active surveillance. Results.—Expert panelists identified pathologic parameters important for management and the related diagnostic and reporting issues. Consensus recommendations were generated where appropriate. Conclusions.—Active surveillance is an important management option for men with low-risk prostate cancer. Vital to this process is the critical role pathologic parameters have in identifying appropriate candidates for active surveillance. These findings need to be reproducible and consistently reported by surgical pathologists with accurate pathology reporting.This publication has 152 references indexed in Scilit:
- Cancer biomarkersMolecular Oncology, 2012
- Role of Prostate Specific Antigen and Immediate Confirmatory Biopsy in Predicting Progression During Active Surveillance for Low Risk Prostate CancerJournal of Urology, 2011
- PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocolsWorld Journal of Urology, 2010
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised DiseaseEuropean Urology, 2010
- Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin LigasesMolecular Cell, 2009
- Outcomes of Localized Prostate Cancer Following Conservative ManagementJAMA, 2009
- Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancerCancer, 2009
- Pathological Upgrading and Up Staging With Immediate Repeat Biopsy in Patients Eligible for Active SurveillanceJournal of Urology, 2008
- Quantifying the role of PSA screening in the US prostate cancer mortality declineCancer Causes & Control, 2007
- Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and TreatmentJournal of Urology, 2007